



# REPORT OF AN INFORMAL WORKING GROUP MEETING ON UROGENITAL SCHISTOSOMIASIS AND HIV TRANSMISSION

Geneva, Switzerland, 1–2 October 2009





**Report of an informal working group on  
urogenital schistosomiasis and HIV transmission**

**Geneva, Switzerland, 1–2 October 2009**



© World Health Organization 2010

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Further information is available at:

Information Resource Centre, World Health Organization, 1211 Geneva 27, Switzerland

Fax: + (41) 22 791 4285, e-mail: [ntddocs@who.int](mailto:ntddocs@who.int)

WHO/HTM/NTD/PCT/2010.5

# Table of contents

<b>Preface -----</b>	<b>v</b>
<b>1. Background -----</b>	<b>1</b>
1.1 History and terminology	1
1.2 Female genital schistosomiasis	1
1.3 Male genital schistosomiasis	2
<b>2. Epidemiology, pathophysiology and pathology -----</b>	<b>3</b>
2.1 Frequency of female and male genital schistosomiasis	3
2.2 Organ involvement according to age	4
2.3 Association with sexually transmitted infections	4
<b>3. Association between female genital schistosomiasis and HIV infection -----</b>	<b>5</b>
3.1 Biological plausibility	5
3.1.1 Impaired barrier function	5
3.1.2 Modulation of immune response	6
3.2 Epidemiological evidence	6
3.2.1 Spatial overlap	6
3.2.2 Temporal association	7
3.2.3 Other epidemiological evidence	7
3.3 Knowledge gaps	7
3.3.1 Link between female genital schistosomiasis and acquisition of HIV infection	7
3.3.2 Link between schistosomiasis and progression of HIV infection	7
3.4 Methodological challenges	8
3.5 Ethical issues	9
<b>4. Diagnosis -----</b>	<b>9</b>
4.1 Overview	9
4.1.1 Syndromic approach	9
4.1.2 Clinical diagnosis	10
4.1.3 Colposcopic diagnosis	10
4.1.4 Microscopic diagnosis	10
4.1.5 Immunological disease markers and PCR	10
4.1.6 Ultrasound	11
4.2 Knowledge gaps	11
4.2.1 Validity of available diagnostic techniques	11
4.2.2 Validity of a clinical algorithm	11
<b>5. Treatment -----</b>	<b>12</b>
5.1 Overview	12
5.2 Knowledge gaps	13
<b>6. Recommendations -----</b>	<b>13</b>
6.1 Terminology	13
6.2 Diagnosis	13
6.2.1 Colposcopy validation study	13
6.2.2 Classification of the clinical pathology of the cervix	14
6.2.3 Validation of a clinical algorithm	14
6.2.4 Validation of putative laboratory disease markers	14
6.3 Studies of the association between female genital schistosomiasis and risk for HIV infection	15

6.3.1 Opportunities	15
6.3.2 New studies	15
6.3.3 The ‘ideal’ study	16
6.3.4 Mathematical modelling	16
6.4 Capacity-building	16
6.5 Ethical issues for research protocols	16
<b>7.Public health recommendations -----</b>	<b>16</b>
<b>8.Conclusions -----</b>	<b>17</b>
<b>References -----</b>	<b>18</b>
<b>Annexes -----</b>	<b>23</b>
I.Ethical issues	23
II..Research subgroups and timelines	24
III..List of participants	25

## Preface

Recent investigations have provided information about a possible association between urogenital schistosomiasis and human immunodeficiency virus (HIV) infection, but the available epidemiological evidence is not sufficient to make policy recommendations. The Bill & Melinda Gates Foundation convened a meeting in Seattle, Washington, United States of America, in April 2009 to review the existing evidence for an association between *Schistosoma haematobium* infection and risk for HIV infection among women and to determine whether there are short-term opportunities to gain additional knowledge rapidly. The Gates Foundation is considering multiple investments: for retrospective analysis of adults enrolled in a cohort of couples discordant for HIV infection to determine whether there is an association between HIV status and *S. haematobium* infection, and for an investigation of whether current schistosomiasis control programme recommendations are sufficient to prevent female urogenital schistosomiasis, by cross-sectional follow-up of previously treated women and a study of prospective treatment of schoolgirls.

WHO convened an informal working group to address: methodological issues, such as the diagnosis and clinical description of female genital schistosomiasis; opportunities for integrating new studies into existing large-scale schistosomiasis treatment programmes; and ethically acceptable designs for such prospective studies. Agreement on these guidelines opens the door for further investment in studies of the potential causal association between urogenital schistosomiasis and HIV infection.

预览已结束，完整报告链接和二维码如下

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_29056](https://www.yunbaogao.cn/report/index/report?reportId=5_29056)